Patients with a rare blood disease in which the immune system attacks their own red blood cells now have, for the first time, a treatment approved specifically for their condition.
The Food and Drug Administration approved Imaavy for warm autoimmune hemolytic anemia in adults and children 12 and older who are currently taking or have previously taken corticosteroids. Johnson & Johnson announced the decision on August 24, 2026. The drug, known generically as nipocalimab-aahu, was granted priority review earlier in the year and was already approved for generalized myasthenia gravis.
Until now, people with the condition were managed with steroids and broad immunosuppressants, drugs developed for other purposes that suppress the whole immune system rather than targeting the antibodies driving the disease. None carried an approval for this use.
The practical meaning for households is specific. This is a condition that produces crushing fatigue, repeated transfusions, and long stretches on steroids with all the side effects that entail. An approved option changes what a hematologist can prescribe, what an insurer is being asked to cover, and what a patient can reasonably ask about at the next appointment.
A Disease That Turns the Immune System Against the Blood
In warm autoimmune hemolytic anemia, IgG autoantibodies bind to red blood cells and destroy them, leaving patients anemic. Roughly one to three new cases per 100,000 people occur each year, and about one in 8,000 people is living with it.
It affects women and men, can appear at any age, and becomes more common after 50. The consequences extend beyond low hemoglobin. Patients face raised risks of venous blood clots, acute kidney failure, and infection, and the company describes the condition as carrying a significantly increased risk of illness and death.
Fatigue is the symptom patients report most often. Karen Jones, president and executive director of the advocacy group wAIHA Warriors, described the pattern in a statement issued with the approval. Patients cycle through periods of feeling like themselves again, she said, and then "their hemoglobin drops, the exhaustion returns, and they're back to square one." The company noted that Jones was not compensated for media work.
The Evidence Behind the Decision
The approval rests on a single pivotal trial, and the details matter.
ENERGY was a multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study in adults, registered as NCT04119050. It randomized 115 adults roughly evenly across two nipocalimab dose schedules and placebo, with 24 weeks of blinded treatment followed by an open-label extension.
The primary endpoint was a durable hemoglobin response, defined as a hemoglobin level of at least 10 grams per deciliter plus an increase of at least 2 grams per deciliter from baseline, sustained for at least 28 days without rescue therapy, with the criteria first met by week 16. Roughly three times as many patients on the approved dose reached that mark as those on placebo by 24 weeks, a difference the company reports as statistically significant. Patients in that group showed a mean increase in hemoglobin of 1 g/dL at week 1.
On fatigue, as measured by a standard questionnaire, the treatment group scored 3.51 points better than the placebo group at week 24. The company states that this and several other figures are considered descriptive under the trial's prespecified statistical plan, meaning they were not formally tested for statistical significance and should be read as supportive rather than conclusive.
Two caveats belong here rather than being buried later. The trial enrolled adults, while the approval extends to patients 12 and older. And full results were presented at the European Hematology Association congress in June rather than published in a peer-reviewed journal at the time of approval.
David Kuter, M.D., D.Phil., a distinguished physician at Massachusetts General Hospital and professor of medicine at Harvard Medical School, said the finding that matters is durability. More patients on the drug achieved a durable hemoglobin response than on placebo, he said, meaning "their red blood cell levels went up and stayed up." Kuter has served as a consultant to Johnson & Johnson and, according to the company, was not paid for media work.
Side Effects and Who Should Be Cautious
Imaavy is administered as an intravenous infusion and works by blocking the neonatal Fc receptor, thereby lowering circulating IgG levels while preserving B-cell function.
The most common adverse reactions reported in these patients were swelling in the hands, ankles, or feet, diarrhea, and fever. Because the drug reduces antibodies that fight infection, it can increase the risk of infection, and the full prescribing information directs clinicians to treat an active infection or to delay an infusion until it clears. Allergic and infusion-related reactions can occur, including during or in the weeks after an infusion.
People taking it should not receive live vaccines. Anyone who is pregnant, planning a pregnancy, or breastfeeding should discuss it with their clinician, as effects on a fetus or infant are not established and a pregnancy safety study is in place.
Access, Cost, and the Realistic Next Step
First-in-class drugs for rare conditions typically carry high list prices and require prior authorization. No price has been announced. Patients should expect insurers to request documentation of the diagnosis and of prior corticosteroid use, which is included in the approved indication.
Johnson & Johnson says a patient support program offers educational resources, a nurse navigator, and cost support options regardless of insurance type. Patients facing a denial can ask their hematologist about appeals, and infusion scheduling should be discussed early because infusion chair availability varies by health system.
No one should stop steroids or any current medication on their own. The approval adds an option for a specialist to consider; it does not automatically change anyone's regimen. People with unexplained severe fatigue, shortness of breath, jaundice, or dark urine should seek medical evaluation, and chest pain, fainting, or severe breathlessness warrants urgent care.
MedicalDaily will report pricing, payer coverage decisions, and peer-reviewed publication of the ENERGY results as they become available.
Key Questions Answered
What is warm autoimmune hemolytic anemia? A rare disease in which IgG autoantibodies attach to red blood cells and destroy them, causing anemia, severe fatigue, and a raised risk of blood clots, kidney failure, and infection.
Who can be prescribed Imaavy for it? Adults and children 12 and older who are currently taking or have previously taken corticosteroids for the condition.
How is it given? By intravenous infusion. The approved dose is 30 milligrams per kilogram every four weeks.
What are the most common side effects? Swelling in the hands, ankles, or feet, diarrhea, and fever. The drug can also increase infection risk, and allergic or infusion-related reactions can occur.
How strong is the evidence? It comes from one randomized, placebo-controlled trial of 115 adults that met its primary endpoint on durable hemoglobin response. Several supporting figures, including the fatigue result, are descriptive rather than formally tested.
Will insurance cover it? Coverage has not been announced. Prior authorization is likely, and documentation of diagnosis and prior steroid use will probably be requested.
Should patients stop their steroids now that a treatment is approved? No. Corticosteroid changes must be managed by the treating clinician, and stopping abruptly can be dangerous.
